Connect Biopharma (CNTB) Fundamental Analysis: Revenue, Earnings & Valuation

2.61 / 10

Underperform

Fundamental analysis rates CNTB as underperform with a composite score of 2.61. Strengths include a strong interest‑coverage ratio and favorable Revenue‑MV, while weaknesses lie in high current‑liabilities ratio, low PB‑ROE and negative revenue growth, indicating limited financial resilience.

Analysis Checks(7/10)

Revenue-MV

Value-7.00

Score3/3

Weight45.53%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-99.75

Score2/3

Weight0.63%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-5.19%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value95.30

Score1/3

Weight-7.26%

1M Return-1.69%

PB-ROE

Value0.18

Score1/3

Weight36.79%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-1.61%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-5.28%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-99.75

Score2/3

Weight0.25%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-4.99%

1M Return-1.13%

Asset-MV

Value-0.49

Score1/3

Weight41.13%

1M Return6.31%

Is CNTB undervalued or overvalued?

CNTB scores 2.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.73% ROE, -6466.80% net margin, -3.90 P/E ratio, 3.47 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.